US bill against outsourcing of call centers gets 106 co-sponsors

April 13, 2012

iti


Washington, April 13: A Congressional bill that bars the US companies outsourcing call center jobs from receiving federal grants and loans now has over 100 co-sponsors, its promoter has said.


The US Call Center and Consumer Protection Act (HR 3596), introduced in the US House of Representatives by Congressman Tim Bishop now has as many as 106 lawmakers as its co-sponsors.

In a statement, Bishop hoped this would compel a hearing on the legislation in the Committee on Energy and Commerce.

The US Call Center and Consumer Protection Act, if passed by the Congress and signed into law, would require the US Department of Labor to track firms that move call center jobs overseas; the firms would then become ineligible for any direct or indirect federal loans or loan guarantees for five years.

"The provision is partially a response to the practice of companies taking millions in incentives from local taxpayers to open call centers in the US, only to off-shore their operations a short time later and leave local communities devastated and still paying the bill," Bishop said.

The bill also requires overseas call centre employees to disclose their location to US consumers and gives customers the right to be transferred to a US-based call centre upon request. "Recent reports of theft and misuse of sensitive information from British and Australian customers of Asian call centers are deeply disturbing, and it is impossible to believe that the financial and medical information of Americans has not been similarly compromised," Bishop said.

"It is clear that overseas call centers simply cannot provide the same level of security for sensitive personal data as facilities in the US, and Americans should be guaranteed the option of a domestic call center to conduct their business. Taxpayer dollars should not be supporting companies that choose protecting their bottom line over protecting their customers," the Congressman said.

"American companies should be taking all measures necessary to protect the identities and personal information of their customers, and these incidents strengthen the case to keep call centers in the US," said Congressman Michael Grimm, a former FBI agent.

"Furthermore, it is important that we do all we can to preserve American jobs and prevent them from moving overseas. This bill ensures that companies receiving taxpayer-funded federal aid or tax incentives don't use those incentives to move their call centers abroad," Grimm said.

The Communications Workers of America (CWA), who represent 150,000 call center employees across the US, have supported US Call Center and Consumer Protection Act.

"Americans are fed up with good-paying, family-supporting call center jobs here in the US being shipped overseas," said CWA chief of staff Ron Collins, who began his career in a US-based Verizon call center.

"Now, to hear that personal information is being stolen at overseas call centers just days after T-Mobile USA announces it will be closing seven call centers in the USA -- affecting 3,300 American workers - just makes your blood boil," Collins said.


Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
July 29,2020

If everything goes as Russia’s expectation, it will be world’s first country to approve a coronavirus vaccine for widespread in the second week of August despite safety and efficacy concerns, according to a report. The adenoviral vector-based vaccine developed by Russian military and government researchers is currently in phase 2 trials.

According to a report from CNN, Russian officials are hoping to get approval for the COVID-19 vaccine developed by the Moscow-based Gamaleya Institute on Agust 10 or even before that. The officials told the outlet that the vaccine will be approved for public use with frontline healthcare workers receiving it first.

“It’s a Sputnik moment,” said Kirill Dmitriev, head of Russia’s sovereign wealth fund, which is financing Russian vaccine research, referring to the successful 1957 launch of the world’s first satellite by the Soviet Union, according to CNN.

“Americans were surprised when they heard Sputnik’s beeping. It’s the same with this vaccine. Russia will have got there first,” he was quoted as saying.

However, Russia is yet to release the scientific data on its coronavirus vaccine trials, hence, questions remain about the safety and efficacy of the vaccine, said the report. The vaccine is in the second phase of testing with developers planning to launch the phase 3 trials sometime after August 3.

Earlier, Interfax reported, citing Health Minister Mikhail Murashko, that the vaccine will be widely used in parallel with phase 3 trials. He said the country plans to vaccinate medics who are at high-risk for COVID-19 next month before clinical trials are completed.

Murashko added that individuals at higher risk of getting infected with the coronavirus such as older people or those with health conditions will also be prioritised for the vaccine, although he did not estimate or reveal when that would happen. The minister added 800 people will be recruited for the phase 3 trials.

Meanwhile, health officials were more cautious considering the fact that human testing of the vaccine is incomplete, and the state registration is expected to begin after August 3, reported The Moscow Times.

On Monday, Moderna and Pfizer announced the commencement of the final phase 3 trials of their candidate vaccines against the SARS-CoV-2 virus, which has so far claimed at least 654,477 lives and infected 16,514,500 people worldwide. 

Researchers will recruit up to 30,000 volunteers in separate trials both backed by the US government. India's first indigenous coronavirus vaccine, COVAXIN, is undergoing phase 1 human clinical trials across the country. More than 150 COVID-19 vaccines are being developed all over the world with at least six candidates already in late-stage clinical trials.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 9,2020

Jun 9: The World Health Organization says it still believes the spread of the coronavirus from people without symptoms is “rare,” despite warnings from numerous experts worldwide that such transmission is more frequent and likely explains why the pandemic has been so hard to contain.

Maria Van Kerkhove, WHO''s technical lead on COVID-19 said at a press briefing on Monday that many countries are reporting cases of spread from people who are asymptomatic, or those with no clinical symptoms.

But when questioned in more detail about these cases, Van Kerkhove said many of them turn out to have mild disease, or unusual symptoms.

Although health officials in countries including Britain, the U.S. and elsewhere have warned that COVID-19 is spreading from people without symptoms, WHO has maintained that this type of spread is not a driver of the pandemic and is probably accounts for about 6 per cent of spread, at most.

Numerous studies have suggested that the virus is spreading from people without symptoms, but many of those are either anecdotal reports or based on modeling.

Van Kerkhove said that based on data from countries, when people with no symptoms of COVID-19 are tracked over a long period to see if they spread the disease, there are very few cases of spread.

“We are constantly looking at this data and we''re trying to get more information from countries to truly answer this question,” she said. “It still appears to be rare that asymptomatic individuals actually transmit onward.”

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.